| 25.04 22:16 | MÄRKTE USA/Wall Street deutlich im Minus - Meta knicken ein |
| 25.04 18:35 | MÄRKTE USA/Börsen kräftig im Minus - Meta knicken ein |
| 25.04 15:53 | MÄRKTE USA/Börsen starten kräftig im Minus - Preisdaten und Meta belasten |
| 25.04 15:39 | dpa-AFX: *MERCK & CO IM DOW VORNE MIT +3,8% - US-PHARMAKONZERN ERHÖHT PROGNOSE |
| 25.04 15:06 | MÄRKTE USA/US-Börsen von Preisdaten und Meta massiv belastet |
| 25.04 13:50 | dpa-AFX: US-Pharmakonzern Merck & Co erhöht Prognose |
| 25.04 13:50 | US-Pharmakonzern Merck & Co erhöht Prognose |
| 25.04 13:45 | dpa-AFX: US-Pharmakonzern Merck & Co erhöht Prognose |
| 25.04 13:05 | dpa-AFX: Merck Lifts FY24 Outlook After Higher Q1 Earnings, Above Market; Stock Up In Pre-market |
| 25.04 12:40 | dpa-AFX: *MERCK Q1 GAAP NET INCOME $4.762 BLN; NON- GAAP NET INCOME $5.279 BLN |
| 25.04 12:39 | dpa-AFX: *MERCK LIFTS AND NARROWS FY NON-GAAP EPS VIEW RANGE TO BE BETWEEN $8.53 AND $8.65 |
| 25.04 12:39 | dpa-AFX: *MERCK LIFTS AND NARROWS FY WORLDWIDE SALES VIEW RANGE TO BE BETWEEN $63.1 BLN AND $64.3 BLN |
| 25.04 12:38 | dpa-AFX: *MERCK Q1 TOTAL WORLDWIDE SALES $15.8 BLN, UP 9% FROM LAST YEAR |
| 25.04 12:31 | dpa-AFX: *MERCK Q1 GAAP EPS $1.87; NON-GAAP EPS $2.07 |
| 25.04 12:05 | MARKT USA/Meta und US-BIP geben Richtung vor |
| 24.04 16:26 | dpa-AFX: *IMMUTEP: PHASE IIB TRIAL SHOWS POSITIVE RESULTS IN FIRST-LINE HNSCC TREATMENT WITH EFTILAGIMOD ALPHA |
| 24.04 04:09 | dpa-AFX: Hanmi, Merck Collaborate To Evaluate BH3120 + Keytruda Combination In Metastatic Solid Tumors |
| 24.04 03:34 | dpa-AFX: *HANMI, MERCK TO EVALUATE 'BH3120'- KEYTRUDA IN PHASE 1 TRIAL IN PROGRESSIVE OR METASTATIC SOLID TUMOR |
| 19.04 13:42 | dpa-AFX: Health Canada Approves Merck's Keytruda Plus Chemotherapy To Treat Gastric Cancers |
| 19.04 13:14 | dpa-AFX: *MERCK: HEALTH CANADA APPROVES KEYTRUDA PLUS CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF GASTRIC CANCERS IN ADULTS |
|
|
